Rhythm Pharmaceuticals, Inc.
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) dā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$91.31
Price+4.49%
$3.92
1Y
Price
Market Cap
$6.258b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-87.1%
EBITDA Margin-92.6%
Net Profit Margin-73.5%
Free Cash Flow Margin-87.1%
EBITDA Margin-92.6%
Net Profit Margin-73.5%
Free Cash Flow MarginRevenue
$217.165m
+14.4%
1y CAGR+42.8%
3y CAGR+89.0%
5y CAGREarnings
-$202.680m
-3.1%
1y CAGR-6.6%
3y CAGR-5.4%
5y CAGREPS
-$3.13
-0.6%
1y CAGR-2.6%
3y CAGR+0.2%
5y CAGRBook Value
$122.906m
$442.316m
Assets$319.410m
Liabilities$227.018m
DebtDebt to Assets
51.3%
-1.2x
Debt to EBITDAFree Cash Flow
-$120.462m
-3.3%
1y CAGR+3.6%
3y CAGR+8.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company